Myricx Expands its Leadership Team with the Appointment of Dr. Robert McLeod as VP Clinical Development
LONDON, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery and development...
Cancer
Mainz Biomed’s ColoFuture Study, Evaluating its Novel mRNA Biomarkers, Reports Groundbreaking Topline Results Demonstrating Sensitivity for Colorectal Cancer of 94% with Specificity of 97% and Advanced Adenoma Sensitivity of 81%
Multiple novel mRNA biomarkers identified for potential integration into pivotal FDA PMA clinical trial (ReconAAsense) BERKELEY, Calif. and MAINZ, Germany,...
Ryvu Therapeutics Reports 2023 Half-Year Financial Results and Provides Corporate Update
The total operating revenues amounted to $7.9M and increased by 131% compared to H1 2022.Updated clinical and preclinical data on...
AngioDynamics to Report Fiscal 2024 First Quarter Financial Results on October 4, 2023
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in...
The Fibroid Foundation Celebrates 10 Years of Advocacy
ROCKVILLE, MD / ACCESSWIRE / September 12, 2023 / The Fibroid Foundation is celebrating 10 years of advocacy and hosting...
30 Years of Groundbreaking Medical Education Features Award-Winning Speakers
CEO and Founder of Neurovations Dr. Eric Grigsby Celebrates Three Decades of Innovation in Chronic Pain Management at 30th Napa...
GoodCap Pharmaceuticals Announces Publication of Positive Results from Two Studies Relating to GoodCap’s Lead Drug Candidate
Toronto, Ontario--(Newsfile Corp. - September 12, 2023) - GoodCap Pharmaceuticals Inc. ("GoodCap" or the "Company"), a leading biopharmaceutical company focused...
Napo Pharmaceuticals, a Jaguar Health Family Company, Submits Funding Application to National Institute of Allergy and Infectious Diseases for Development of NP-300 Drug Candidate for Cholera-Related Diarrhea
Cholera is an acute diarrheal illness caused by infection of the intestine with the bacterium Vibrio choleraeJaguar intends to pursue...
Cosmos Health Introduces Guidance; Expects to Achieve Over $180M in Gross Annual Revenue and EBITDA in Excess of $20M by 2026; Recaps Significant Events Reported So Far in 2023
Company reaches major strategic inflection point, with operations and revenue ramp-up underwayInaugural 2026 guidance introduced; target to achieve:More than $180...
TRIANA Biomedicines Announces the Appointments of Vito Palombella as Chief Scientific Officer and Reza Mazhari as Chief Business Officer
Appointments strengthen the leadership team and deepen expertise in drug discovery, oncology research, and strategic partnershipsDr. Brian Jones appointed to...
CureVac Advances Seasonal Flu Study to Phase 2 in Collaboration with GSK Following Selection of Promising mRNA Vaccine Candidate with Broad Coverage
Phase 1 part of combined Phase 1/2 study assessed comprehensive series of flu vaccine candidates, featuring up to eight separate...
SomaLogic researchers identify key proteins to aid in early detection of lung, colon and breast cancer and ovarian tumors
SomaLogic’s SomaScan® platform was used to target 15 markers shared among all cancer types.BOULDER, Colo., Sept. 12, 2023 (GLOBE NEWSWIRE)...
Sorrento Announces Phase 3 Trial Met Primary Endpoint and Key Secondary Endpoint in Mild or Moderate COVID-19 Adult Patients Treated with Ovydso (Olgotrelvir), an Oral Mpro Inhibitor as a Standalone Treatment for COVID-19
In the phase 3 trial, a randomized double blind and placebo-controlled pivotal study, 1,212 mild or moderate COVID-19 patients were...
Bolt Biotherapeutics Announces Issuance of U.S. Patent Covering Dectin-2-Targeting Agonist Antibodies, Including BDC-3042
REDWOOD CITY, Calif., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel...
IO Biotech Announces New Data Related to its IO102-IO103 Therapeutic Cancer Vaccine Presented Today at the IASLC 2023 World Conference on Lung Cancer
Encouraging interim data support the potential of IO102-IO103 in combination with pembrolizumab as first-line treatment in non-small cell lung cancerNEW...
A Phase 2 Study of Anti-Siglec-15 Antibody, NC318, in Combination with Pembrolizumab (NCT04699123) Demonstrates Clinical Activity in Patients with Advanced PD-1 Axis Inhibitor Refractory NSCLC
• Data presented at the 2023 World Conference on Lung Cancer hosted by the International Association for the Study of...
Spinogenix Awarded $3 Million NIH Grant to Support Continued Development of SPG302, the First Synaptic Regenerative Therapeutic for Alzheimer’s Disease
Treatment Could Help Restore Brain Functions Lost in Many Neurogenerative DisordersSAN DIEGO, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Spinogenix, Inc.,...
Lisata Therapeutics Announces First Patient Treated in the BOLSTER Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide, in Patients with Advanced Solid Tumors
Phase 2a double-blind, placebo-controlled, multi-center, randomized study evaluating LSTA1 in combination with standards of care versus standards of care alone...
Breakthrough: GeneType for Pancreatic Cancer, Melanoma, and Atrial Fibrillation Cleared for Australian Release
Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) Expands Reach of Revolutionary geneType Multi-Risk Test in Australia: A major advancement towards...
PROCEPT BioRobotics® Receives U.S. FDA Investigational Device Exemption to Investigate Aquablation® Therapy for Prostate Cancer
REDWOOD CITY, Calif., Sept. 12, 2023 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (NASDAQ: PRCT) (“PROCEPT BioRobotics”), a global leader in...